| # | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ALA4705283 | B | Inhibition of N-terminal GFP tagged human DOCK5 (1212-1642 residues) expressed in HEK293T cells assessed as reduction in exchange activity incubated for 1 hr by Western blot analysis based Rac-GTP pull-down assay | Homo sapiens | 11 | cell-based format | Scientific Literature | ||
| 2. | ALA4705284 | F | Inhibition of resorption activity of mouse peripheral blood cell-derived osteoclasts at 5-10 uM incubated for 48 hrs by Kossa-staining based assay | Mus musculus | 10 | tissue-based format | Scientific Literature | ||
| 3. | ALA4705286 | B | Inhibition of C-terminal 6-histidine tagged human DOCK5 (1212 to 1642 residues) expressed in Escherichia coli assessed as reduction in nucleotide exchange efficiency at 20 to 60 uM by N-methylanthraniloyl-GDP fluorescence based nucleotide exchange assay | Homo sapiens | 10 | assay format | Scientific Literature | ||
| 4. | ALA4705287 | B | Inhibition of C-terminal 6-histidine tagged human TRIOGEF1 (R1232 to T1550 residues) expressed in Escherichia coli assessed as reduction in nucleotide exchange efficiency at 20 to 60 uM by N-methylanthraniloyl-GDP fluorescence based nucleotide exchange assay | Homo sapiens | 2 | assay format | Scientific Literature | ||
| 5. | ALA4705288 | T | Toxicity in mouse peripheral blood cell-derived osteoclasts assessed as reduction in osteoclasts number up to 20 uM incubated for 48 hrs by TRAP-staining based assay | Mus musculus | 1 | tissue-based format | Scientific Literature | ||
| 6. | ALA4705290 | F | Inhibition of resorption activity of mouse peripheral blood cell-derived osteoclasts at 1-20 uM incubated for 48 hrs by Kossa-staining based assay | Mus musculus | 3 | tissue-based format | Scientific Literature | ||
| 7. | ALA4705291 | F | Inhibition of resorption activity of mouse peripheral blood cell-derived osteoclasts incubated for 48 hrs by Kossa-staining based assay | Mus musculus | 1 | tissue-based format | Scientific Literature | ||
| 8. | ALA4705294 | T | Toxicity in C57BL6/J mouse model of OVX-induced bone loss assessed as effect on body weight at 20 mg/kg, IP QD for 4 weeks | Mus musculus | 1 | organism-based format | Scientific Literature | ||
| 9. | ALA4705295 | T | Toxicity in C57BL6/J mouse model of OVX-induced bone loss assessed as effect on body weight at 20 mg/kg, IP BID for 4 weeks | Mus musculus | 1 | organism-based format | Scientific Literature | ||
| 10. | ALA4705296 | T | Toxicity in C57BL6/J mouse model of OVX-induced bone loss assessed as effect on osteoclast numbers per bone perimeter at 20 mg/kg, IP BID for 4 weeks | Mus musculus | 1 | organism-based format | Scientific Literature | ||
| 11. | ALA4705297 | T | Toxicity in C57BL6/J mouse model of OVX-induced bone loss assessed as effect on osteoclast numbers per bone perimeter at 20 mg/kg, IP QD for 4 weeks | Mus musculus | 1 | organism-based format | Scientific Literature | ||
| 12. | ALA4705307 | F | Antiosteoporotic activity in C57BL6/J mouse model of OVX-induced bone loss assessed as trabecular bone volume per tissue volume level in femoral metaphysis at 20 mg/kg, ip QD for 4 weeks by histomorphometry (11.67 +/- 2.37%) | Mus musculus | 1 | organism-based format | Scientific Literature | ||
| 13. | ALA4705308 | F | Antiosteoporotic activity in C57BL6/J mouse model of OVX-induced bone loss assessed as trabecular thickness level in femoral metaphysis at 20 mg/kg, ip QD for 4 weeks by histomorphometry (39.96 +/- 5.42 um) | Mus musculus | 1 | organism-based format | Scientific Literature | ||
| 14. | ALA4705309 | F | Antiosteoporotic activity in C57BL6/J mouse model of OVX-induced bone loss assessed as trabecular number level in femoral metaphysis at 20 mg/kg, ip QD for 4 weeks by histomorphometry (2.99 +/- 0.80 /mm) | Mus musculus | 1 | organism-based format | Scientific Literature | ||
| 15. | ALA4705310 | F | Antiosteoporotic activity in C57BL6/J mouse model of OVX-induced bone loss assessed as trabecular separation level in femoral metaphysis at 20 mg/kg, ip QD for 4 weeks by histomorphometry (319.80 +/- 106.52 um) | Mus musculus | 1 | organism-based format | Scientific Literature | ||
| 16. | ALA4705311 | F | Antiosteoporotic activity in C57BL6/J mouse model of OVX-induced bone loss assessed as trabecular bone volume per tissue volume level in tibial metaphysis at 20 mg/kg, ip QD for 4 weeks by microCT analysis (17.49 +/- 2.91 %) | Mus musculus | 1 | organism-based format | Scientific Literature | ||
| 17. | ALA4705312 | F | Antiosteoporotic activity in C57BL6/J mouse model of OVX-induced bone loss assessed as trabecular pattern factor level in tibial metaphysis at 20 mg/kg, ip QD for 4 weeks by microCT analysis (17.17 +/- 3.41 um/day) | Mus musculus | 1 | organism-based format | Scientific Literature | ||
| 18. | ALA4705313 | F | Antiosteoporotic activity in C57BL6/J mouse model of OVX-induced bone loss assessed as degree of anisotropy (range 0-1) level in tibial metaphysis at 20 mg/kg, ip QD for 4 weeks by microCT analysis (0.53 +/- 0.07 No_unit) | Mus musculus | 1 | organism-based format | Scientific Literature | ||
| 19. | ALA4705314 | F | Antiosteoporotic activity in C57BL6/J mouse model of OVX-induced bone loss assessed as structure model index level in tibial metaphysis at 20 mg/kg, ip QD for 4 weeks by microCT analysis (1.92 +/- 0.19 No_unit) | Mus musculus | 1 | organism-based format | Scientific Literature | ||
| 20. | ALA4705315 | F | Antiosteoporotic activity in C57BL6/J mouse model of OVX-induced bone loss assessed as cortical thickness level in tibial diaphysis at 20 mg/kg, ip QD for 4 weeks by microCT analysis (179.27 +/- 7.57 um) | Mus musculus | 1 | organism-based format | Scientific Literature |
The page will load shortly, Thanks for your patience!